Loading...
•
Dec 31, 2025
Boston Scientific Q4 2025 Earnings Report
Reported strong fourth-quarter results with double-digit revenue growth and higher earnings year over year.
Key Takeaways
Boston Scientific delivered strong Q4 2025 performance with robust revenue growth led by Cardiovascular, higher profitability, and adjusted EPS expansion.
Revenue grew strongly year over year, driven by Cardiovascular and MedSurg.
GAAP net income and EPS increased compared to the prior-year quarter.
Adjusted EPS significantly exceeded the prior-year period.
Broad-based regional growth supported overall performance.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
The company provided guidance for continued growth in 2026 with strong revenue and earnings momentum.
Positive Outlook
- Expected full-year 2026 reported revenue growth of 10.5% to 11.5%.
- Organic revenue growth expected between 10.0% and 11.0% for 2026.
- Adjusted EPS guidance of $3.43 to $3.49 for full-year 2026.
- Continued strength anticipated in Cardiovascular portfolio.
- Broad regional growth expected to continue.
Challenges Ahead
- Potential foreign currency headwinds.
- Integration risks from recent acquisitions.
- Ongoing macroeconomic uncertainty.
- Regulatory and reimbursement risks.
- Potential variability in procedural volumes.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...